The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Summer 2022 RFP: The Edmond J. Safra Movement Disorders Research Career Development Award, 2022Tracking Eye Movements and Pupil Responses as a Diagnostic and Prognostic Biomarker in Parkinsonian Disorders
Study Rationale: We do not currently have accurate tests to diagnose Parkinson’s disease (PD) and the conditions which mimic it (atypical parkinsonism) at a very early stage. Similarly, we do not have...
-
Research Resources, 2022Neural Network Imaging Analysis in Parkinson’s Disease Associated with Parkin Mutation
Study Rationale: Clinical imaging biomarkers are desperately needed to provide a non-invasive means of assessing therapeutic efficacy in clinical trials for Parkinson’s disease (PD). Recent studies...
-
Target Advancement Program, 2021Sex-based Modulation of Neuromelanin-linked Parkinson’s Disease Pathology
Study Rationale:
Parkinson’s disease (PD) is more common in men than in women, and men with PD exhibit earlier onset, faster progression, more severe motor symptoms and more frequent cognitive decline... -
Research Grant, 2020Alpha-synuclein Toxicity in LRRK2 Knock-in Models and Rescue by LRRK2 Silencing
Study Rationale:
Gene mutations that alter the function of the LRRK2 protein are known to increase the risk of developing Parkinson’s disease (PD). One of the pathological hallmarks of PD is the... -
Non-pharmacological Interventions for Gait and Balance, 2019Protective Step Training in People with Parkinson's Disease and Postural Disturbances
Study Rationale:
Falls are a common and challenging symptom of Parkinson's disease. The ability to execute a quick and effective movement after a loss of balance (e.g., a "protective step") may reduce... -
Research Grant, 2016Planning Phase for a Phase IIa Study of Nilotinib in People with Parkinson's Disease
Study Rationale:
Nilotinib, a drug approved for chronic myelogenous leukemia, inhibits the protein c-Abl. Higher brain levels of c-Abl are associated with Parkinson's disease (PD), and laboratory...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.